CAR T cells — Competitive Intelligence Brief

CAR T cells (CAR T cells) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR T cell therapy. Area: Oncology.

phase 3 CAR T cell therapy Tumor-associated antigens (e.g., CD19, BCMA, mesothelin depending on construct) Oncology Biologic

Target snapshot

CAR T cells (CAR T cells) — Memorial Sloan Kettering Cancer Center. CAR T cells are engineered immune cells that recognize and kill cancer cells by expressing chimeric antigen receptors targeting tumor-associated antigens.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAR T cells TARGET	CAR T cells	Memorial Sloan Kettering Cancer Center	phase 3	CAR T cell therapy	Tumor-associated antigens (e.g., CD19, BCMA, mesothelin depending on construct)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR T cell therapy class)

1. AffyImmune Therapeutics, Inc. · 1 drug in this class
2. Allife Medical Science and Technology Co., Ltd. · 1 drug in this class
3. Chongqing Precision Biotech Co., Ltd · 1 drug in this class
4. Hebei Senlang Biotechnology Inc., Ltd. · 1 drug in this class
5. Memorial Sloan Kettering Cancer Center · 1 drug in this class